Partnered Articles
Writing and Publishing
- BioSpace’s Insights team writes and publishes the article
- Includes up to two subject matter expert interviews of your choosing with BioSpace’s Insights team
- Strategic guidance to optimize your content and demonstrate your thought leadership and subject matter expertise
- Metrics provided after publication
- Social promotion to over 230k BioSpace social followers
- Email promotion in our GenePool newsletter for a week
- Featured on the BioSpace homepage for a week
- Long-term content hosting and SEO benefits
- Creative assets provided
- Includes an Article Reprint so you can further leverage your BioSpace article
BioSpace is the leading platform for life sciences news and careers.
Benefit from BioSpace’s search authority, established media presence and reader loyalty. Elevate your brand and make an impression on key biopharma decision-makers to increase market visibility and stand out from your competitors. BioSpace’s life sciences audience continues to grow, with hundreds of thousands of subscribers, social followers and millions of site visitors, so you can feel confident you’re reaching the right people.
1.25m
average monthly website visits
475k
engaged email subscribers
230k
social followers
12k
new registrations every month
With inspections always on the table, LOTTE Biologics is pushing a proactive, quality first culture across its dual hubs in Syracuse and Songdo, backing its new single‑use ADC facility with rigorous training, self‑audits and real‑time regulatory surveillance.
One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical trials. Two employees from its research and development organization discuss why representation matters and the work their team is doing to benefit patients now and in the future.
The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development with drug delivery device design—and leveraging a single‐vendor ecosystem—can deliver significant time, cost, and regulatory advantages for US‑focused drug products, according to industry experts.
As bispecifics, ADCs, protein degraders, and AI-designed mini-proteins move into the clinic, discovery teams face a new bottleneck: engineering and producing molecules whose complexity challenges conventional workflows.
Industry leaders say uncertainty in funding, clinical development and manufacturing is driving companies to embrace digital transformation, streamlined operations and strategic partnerships to navigate a turbulent market and global tariff pressures.
The market outlook is full of uncertainty and pitfalls. Experts weigh in on how to mitigate risks.
